Oded Biran - Rosetta Genomics Insider

ROSG -- USA Stock  

USD 0.43  0.0001  0.0233%

Mr. Oded Biran serves as General Counsel of the company, since November, 2011. Mr. Biran was an independent attorney between the years 20102011, after previously working for us as legal counsel between June and November 2010. Prior to that, Mr. Biran was an associate in the law offices of Sharon Raviv and Co., a boutique law firm specializing in technology and communications, between December 2009 and June 2010. During the years of 2008 and 2009, Mr. Biran was an associate in Raved Magriso, Benkel, Lahav and Co.s, where he practiced in the corporate and securities department, specializing in corporate, technology, IP and complex mergers and acquisitions transactions. During 20062007, Mr. Biran was an associate at Gabriel Reubinoff and Co.s Tel Aviv office where he coheaded the firms class action department
Age: 35  Executive Since 2011      
972 73 222 0700  http://www.rosettagx.com
Biran holds a L.L.B degree from the Hebrew University in Jerusalem and is a member of the Israeli Bar Association.

Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (137.95) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics Ltd has Current Ratio of 2.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 13 records


Walter NootUSANA Health Sciences
Robert SinnottUSANA Health Sciences
Jim BrownUSANA Health Sciences
Daniel KephartNeogen Corporation
Douglas BraunUSANA Health Sciences
James BrambleUSANA Health Sciences
Peony YuFibroGen
Frank ValoneFibroGen
Krishna GortiThe Medicines Company
Mitchall ClarkAtara Biotherapeutics
Daniel MacugaUSANA Health Sciences
Christopher HaqqAtara Biotherapeutics
David MulhamUSANA Health Sciences

Entity Summary

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people.Rosetta Genomics Ltd (ROSG) is traded on Nasdaq Capital Markets in USA. It is located in 10 Plaut Street and employs 86 people.

Rosetta Genomics Leadership Team

David Sidransky, Independent Director
Kenneth Berlin, CEO and Pres
Anne Fields, IR Contact Officer
Joshua Rosensweig, Director
Dganit Bar, Chief Scientific Officer
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee
Douglas Sites, Executive Vice President - Sales and Marketing
Tal YaronEldar, Independent Director
Eti Meiri, Vice President - Research
Robert Wassman, Chief Medical Officer
Oded Biran, General Counsel
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director, Reimbursement-Managed Care
Ron Kalfus, CFO
Gerald Dogon, External Independent Director
Tali YaronEldar, External Independent Director

Stock Performance Indicators

Current Sentiment - ROSG

Rosetta Genomics Investor Sentiment

Most of Macroaxis users are at this time bullish on Rosetta Genomics Ltd. What is your perspective on investing in Rosetta Genomics Ltd? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 70 shares of
2 days ago
Traded for 35.02
Purchased a lot of shares of
2 days ago
Traded for 154.92
Purchased over 20 shares of
2 days ago
Traded for 112.14
Purchased over 300 shares of
2 days ago
Traded for 9.55
Purchased over 400 shares of
2 days ago
Traded for 6.33
Additionally take a look at Your Equity Center. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com